Advertisement

Inflammopharmacology

, Volume 27, Issue 6, pp 1319–1323 | Cite as

Effect of tranexamic acid in improving the lifespan of naturally aging mice

  • Keiichi HiramotoEmail author
  • Yurika Yamate
  • Daijiro Sugiyama
  • Kazunari Matsuda
  • Yasutaka Iizuka
  • Tomohiko Yamaguchi
Short Communication

Abstract

An effective method to improve lifespan is not known. Therefore, in this study, we examined the lifespan-extending effect of tranexamic acid in normal mice. We bred hairless mice without exposure to ultraviolet radiation and psychical stress until they died naturally. During the study period, the mice were orally administered tranexamic acid (12 mg/kg/day) three times weekly. An increase in the lifespan of mice was observed by tranexamic acid administration. Furthermore, age-related diseases of the skin were ameliorated by tranexamic acid administration. Moreover, the blood level of tumor necrosis factor-α, interleukin-6, reactive oxygen species (ROS), and matrix metalloproteinase (MMP)-9 was decreased by tranexamic acid administration. These results indicate that tranexamic acid suppresses the secretion of inflammatory cytokines, MMP-9, and ROS induced by natural aging, ameliorating age-related diseases, and, consequently, extending the lifespan.

Keywords

Interleukin-6 Matrix metalloproteinase-9 Natural aging Reactive oxygen species Tranexamic acid Tumor necrosis factor-α 

Notes

Acknowledgements

This study was supported by JSPS KAKENHI (Grant Number 18K11085).

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest in association with this study.

References

  1. Abu-Taha M, Rius C, Hermenegildo C, Noguere I, Cerda-Nicolas JM, Issekutz AC, Jose PJ, Cortijo J, Morcillo EJ, Sanz MJ (2009) Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol 183:1393–1402CrossRefGoogle Scholar
  2. Arnardottir HH, Dalli J, Colas RA, Shinohara M, Serhan CN (2014) Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol 193:4235–4244CrossRefGoogle Scholar
  3. Franceschi C, Campisi J (2014) Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 69:S4–S9CrossRefGoogle Scholar
  4. Hiramoto K, Yamate Y, Sugiyama D, Matsuda K, Iizuka Y, Yamaguchi T (2018) Tranexamic acid inhibits the plasmin and non-irradiated skin markers of photoaging induced by long-term UVA eye irradiation in female mice. Biomed Pharmacother 107:54–58CrossRefGoogle Scholar
  5. Hiramoto K, Yamate Y, Sugiyama D, Matuda K, Iizuka Y, Yamaguchi T (2019) Ameliorative effect of tranexamic acid on physiological skin aging and its sex difference in mice. Aech Dermatol Res 15:85.  https://doi.org/10.1007/s00403-019-01938-5 CrossRefGoogle Scholar
  6. Isseroff RR, Rifkin DB (1983) Plasminogen is present in the basal layer of the epidermis. J Invest Dermatol 80:297–299CrossRefGoogle Scholar
  7. Ma JF, Sanchez BJ, Hall DT, Tremblay AK, Di Marco S, Gallouzi IE (2017) STAT3 promotes IFNγ/TNFα-induced muscle wasting in an NF-kB-dependent and IL-6-independent manner. EMBO Mol Med 9:622–637CrossRefGoogle Scholar
  8. Manabe I (2017) Inflammaging and age-associated diseases. Jpn J Geriatr 54:105–113CrossRefGoogle Scholar
  9. Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83–89CrossRefGoogle Scholar
  10. Ng W, Jerath A, Wasowicz M (2015) Tranexamic acid: a clinical review. Anaesthesiol Intensiv Ther 47:339–350CrossRefGoogle Scholar
  11. Ohtani N, Imanura Y, Yamakoshi K, Hirota F, Nakayama R, Kubo Y, Ishimaru N, Takahashi A, Hirao A, Shimizy T, Mann DJ, Saya H, Hayashi Y, Arase S, Matsumoto M, Kazuki N, Hara E (2007) Visualizing the dynamics of p21(Waf1/Cip1) cyclin-dependent kinase inhibitor expression in living animals. Proc Natl Acad Sci USA 104:15034–15039CrossRefGoogle Scholar
  12. Okunishi K, Sisson TH, Huang SK, Hogaboam CM, Simon RH, Peters-Golden M (2011) Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. J Biol Chem 286:32231–32243CrossRefGoogle Scholar
  13. Shaw AC, Goldstein DR, Montgomery RR (2013) Age-dependent dysregulation of innate immunity. Nat Rev Immunol 13:875–887CrossRefGoogle Scholar
  14. Shimizu T, Marusawa H (2011) Role of inflammation in the development of gastrointestinal cancers. Nihon Shokakibyo Gakkai Zasshi 108:1374–1382PubMedGoogle Scholar
  15. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 36:1954–1959CrossRefGoogle Scholar
  16. Yamasaki H, Tsuji H, Kitamura M (1967) Anti-inflammatory effect of the antiplasmin agents, epsilon-aminocaproic acid (EACA) and trans-4-aminomethylcyclohexanecarboxylic acid (AMCHA) in rats. Nihon Yakurigaku Zasshi 63:560–571CrossRefGoogle Scholar
  17. Yoshizaki K (2008) Pathogenic analysis of chronic inflammatory disease based on the clinical results by IL-6 blocking therapy. Nihon Rinsho Meneki Gakkai Kaishi 31:104–112CrossRefGoogle Scholar
  18. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:4279–4295CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Keiichi Hiramoto
    • 1
    Email author
  • Yurika Yamate
    • 1
  • Daijiro Sugiyama
    • 2
  • Kazunari Matsuda
    • 2
  • Yasutaka Iizuka
    • 2
  • Tomohiko Yamaguchi
    • 2
  1. 1.Department of Pharmaceutical SciencesSuzuka University of Medical ScienceSuzukaJapan
  2. 2.R&D DepartmentDaiichi Sankyo Healthcare Co., Ltd.TokyoJapan

Personalised recommendations